Homepage - GRAIL GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages
Multi-cancer early detection - GRAIL Multi-cancer early detection (MCED) testing is a new approach to screening for cancer Adding a blood-based multi-cancer early detection test can help screen for many of the deadliest cancers that don’t have recommended screening today 7,8
Careers - GRAIL We have a group of people at GRAIL whose talent, commitment, and creativity are unmatched And as we grow, we’re looking for people who will increase the impact we can make on the world
Clinical Studies - GRAIL We are committed to the utmost scientific rigor and have enrolled over 300,000 participants in a clinical study program to demonstrate broad applicability of our multi-cancer early detection technologies To support and validate our technology, we are partnering with leading community and academic medical centers around the world
Methylation - GRAIL In 2019, GRAIL announced its proprietary methylation technology, which comprises detection of DNA shed into the blood and machine learning, to recognize a “fingerprint” for cancer
Leadership Team - GRAIL To pursue a mission like GRAIL’s, it takes all of us—a unified collective of courageous, adaptable, and open-minded big thinkers dedicated to creating a better world
Galleri Test - GRAIL The Galleri test was developed — and its performance characteristics were determined — by GRAIL The Galleri test has not been cleared or approved by the Food and Drug Administration
About Us - GRAIL GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to screen for many of the deadliest cancer types before symptoms appear
GRAIL and Quest Diagnostics Provide GRAIL’s Galleri® Multi-Cancer Early . . . GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages
Our History - GRAIL The test detected cell-free DNA from cancer present in the mother’s blood In 2016, Illumina spun out a separate entity to focus on researching this incredible discovery, naming it GRAIL because the co-founders believed a simple blood test could be the “holy GRAIL” of cancer detection